Diabetic Drug Metformin May have Protected Diabetic Patients from Severity Of COVID-19

“This study continues to provide justification for further research on metformin for COVID-19. We’re fortunate to have biostatisticians and informatics experts in our Clinical and Translational Science Institute who are exceptional in observational analyses,” said Carolyn Bramante, M.D., an assistant professor at the University of Minnesota Medical School and an internist and pediatrician with M Health Fairview.

reduced the severity of COVID-19 infection.

This study was conducted among adults with type 2 diabetes who were taking medication for their high blood sugar, those taking metformin had a 45% lower risk of needing a breathing machine (ventilator) or dying from COVID-19 than similar individuals who were not taking metformin as their diabetic medication.

Another study, which was conducted earlier this year by Dr. Bramante revealed that metformin lowers the odds of emergency department visits, hospitalizations or death due to COVID-19 (2 Trusted Source
Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19

Go to source

).

How did Metformin, a Diabetic Drug Helped Patients with COVID-19 Infection?

In a study that was conducted a few months ago, it was noted that when metformin was given as a treatment to COVID-19 patients with Diabetes it showed lower markers of inflammation, renal ischemia, and thrombosis, and fewer hospitalized days and intubation requirement (3 Trusted Source
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes

Go to source

).

How did COVID-19 Impact Diabetic Patients?

The COVID-19 pandemic overlapped the preexisting diabetes pandemic to only produce a fast and very vulnerable group of COVID-19 and diabetic patients.

Advertisement


It was clearly established that patients with diabetes mellitus (DM), severe obesity, cardiovascular disease, and hypertension were more likely to be infected with COVID-19 and were at a higher risk of death due to this infection (4 Trusted Source
Unwinding Link between Coronavirus and Diabetes Patient

Go to source

).

But some of the diabetic patients were shielded by the diabetic drug, metformin.
In various test-tube experiments in which metformin stopped the virus from multiplying (5 Trusted Source
Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation

Go to source).

Researchers say metformin is safe, inexpensive, and widely available. Thus, more clinical trials are warranted to further describe the relation between metformin and COVID-19 and other viral infections.

References :

  1. Diabetes medications and associations with Covid-19 outcomes in the N3C database: A national retrospective cohort study – (https://pubmed.ncbi.nlm.nih.gov/36395143/)
  2. Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19 – (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325185/)
  3. Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes – (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764325/)
  4. Unwinding Link between Coronavirus and Diabetes Patient – (https://benthamscience.com/article/121988)
  5. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation – (https://pubmed.ncbi.nlm.nih.gov/34115964)

Source: Medindia

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.